ICER Hands CMS A Drug Price Negotiation Cheat Sheet

Analysis Offered On Eliquis, Xarelto

The drug price assessment group ran cost analyses on two of the first 10 drugs selected for Medicare price negotiations, Eliquis and Xarelto, and submitted the report to the US government.

helping hand
ICER hopes to help CMS with its drug price negotiation program. • Source: Shutterstock

The Institute for Clinical and Economic Review (ICER) is eager to help the US Centers for Medicare & Medicaid Services (CMS) navigate the intricacies of implementing a new drug price negotiation program. ICER has long run price and value assessments for drugs as an independent non-profit organization and has gained some influence in the US when it comes to drug pricing and the formulary negotiation process between drug manufacturers and insurers.

Key Takeaways
  • ICER conducted an evidence assessment of two drugs selected by CMS for the first round of drug price negotiations and submitted them to the government.

Now, ICER is hoping to use the experience it has gained conducting value assessments to guide CMS through a more...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By 

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By 

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Europe’s Drugmakers Lament EU Pharma Package

 
• By 

EFPIA says reforms make the continent less attractive for innovative firms.

More from Scrip

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.